Drugs / ThisCART7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05127135 | Jan 2020 → Jan 2023 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Fundamenta Therapeutics, Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ThisCART7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05127135 ↗ |
| Known as | ThisCART7 cells | “allogeneic anti-CD7 CAR T Cells(ThisCART7 cells) is used to treat patients with refractory or relapsed CD7 positive T cell malignancies” NCT05127135 ↗ |
| Modality | Cell therapy | “Allogeneic CAR-T Targeting CD7” NCT05127135 ↗ |
| Target | CD7 | “Allogeneic CAR-T Targeting CD7” NCT05127135 ↗ |